-
Pharma Supplier Charles River Laboratories Has Leading Competitive Position, Raymond James Says In Upgrade
Thursday, August 23, 2018 - 10:58am | 404Charles River Laboratories Intl. Inc (NYSE: CRL), a provider of products and services to pharmaceutical companies, is a market share leader that's well-positioned for expansion, according to Raymond James. The Analyst Analyst Michael Baker upgraded Charles River Laboratories from...
-
Corcept Therapeutics Is 'Fairly Valued,' Stifel Says In Downgrade
Thursday, May 31, 2018 - 12:52pm | 381Stifel's bullish case for Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company that focuses on drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, no longer applies. The Analyst Stifel's Adam Walsh downgraded...
-
Teva's 'Achievable' 2018 Outlook, Restructuring Plan Trigger Credit Suisse Upgrade
Monday, February 12, 2018 - 10:52am | 392Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced a restructuring program late last year that is now showing some signs of early success, according to Credit Suisse. The Analyst Credit Suisse's Vamil Divan upgraded Teva's stock rating from Neutral to Outperform with a...
-
Here's Why Forward Pharma Lost 30% Today
Monday, January 29, 2018 - 2:17pm | 445Shares of Forward Pharma A/S (NASDAQ: FWP), a Denmark-based clinical-stage biopharmaceutical company, lost around 30 percent Monday after the company announced a disappointing update related to its patent. What You Need To Know Forward Pharma said in a press release the European Patent Office (...
-
The Companies That Led 2017's Biotech Rally
Friday, December 22, 2017 - 10:50am | 811One of 2017's better performers has been the biotech sector, which turned around after a disappointing 2016. Biotech stocks fell steeply early in the year in 2016, weighed down by fears of price control and clampdowns on price gouging. Subsequently, the sector traded in a broad range...
-
Mallinckrodt Sees Slight Positive From Tax Reform, Up To $500 Million Benefit
Friday, December 22, 2017 - 10:06am | 444Mallinckrodt PLC (NYSE: MNK), a generic specialty pharmaceutical company, said Friday in an 8-K filing it expects to see an up to $500 million benefit from President Donald Trump's tax reform plan. What You Need To Know U.S. government officials passed this week the Tax Cut and Jobs Act and...
-
With Rite Aid Uncertainty Behind It, Could Walgreens Go Shopping?
Monday, December 4, 2017 - 2:44pm | 465For more than two years, pharmaceutical giant Walgreens Boots Alliance Inc (NASDAQ: WBA) has been "tap dancing horizontally" with smaller rival Rite Aid Corporation (NYSE: RAD). In the end, Rite Aid agreed to sell Walgreens 1,932 of its stores in a $4.4-billion deal that now frees up...
-
Who Is The Former Pharma Exec Trump Nominated To Lead HHS?
Tuesday, November 14, 2017 - 1:02pm | 555President Donald Trump has nominated Alex Azar, a former pharmaceutical executive, to run the Department of Health and Human Services. What You Need To Know The Department of Health and Human Services is a cabinet-level department of the U.S. federal government with a mission of protecting...
-
For Teva Pharmaceuticals, No Recovery In Sight, Says Analyst
Monday, November 13, 2017 - 1:48pm | 487Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. The Analyst JPMorgan's Chris Schott downgraded Teva's stock rating from Neutral...
-
H.C. Wainwright: Acadia Is More Than A One-Trick Pony
Wednesday, November 8, 2017 - 1:26pm | 309ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Tuesday reported second-quarter earnings, which consisted of a better than expected loss per share (53 cents versus expectations for 62 cents)and a revenue beat ($35.6 million versus expectations for $32.03 million). Sales of the company's only...
-
Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever
Wednesday, October 18, 2017 - 9:07am | 365Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from $65 to $72. The new bullish stance stems from increased conviction of Merck's...
-
Here's Why Exelixis Is Trading Higher By 20%
Monday, October 16, 2017 - 9:16am | 380Shares of Exelixis, Inc. (NASDAQ: EXEL) were trading higher by 20 percent early Monday morning after the company announced an encouraging update for its CABOMETYX (cabozantinib) therapy for the treatment of patients with advanced hepatocellular carcinoma. The U.S. Food and Drug Administration has...
-
Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers
Wednesday, September 20, 2017 - 11:49am | 392Analysts at Goldman Sachs turned bearish on industry giant Johnson & Johnson (NYSE: JNJ) amid valuation concerns. Analyst Jami Rubin downgraded J&J's stock from Neutral to Sell with a price target boosted from $125 to $130, which implies downside from Wednesday's open of $133.25....
-
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
Wednesday, September 13, 2017 - 9:14am | 590Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) said Tuesday it has agreed to sell its Paragard IUD product to Cooper Companies Inc (NYSE: COO) in a $1.1 billion cash deal. Teva also confirmed it will continue divesting the remaining assets it holds within the women's health portfolio along...
-
Valeant's CEO Details The Company's 'Great Progress' And What's Next
Thursday, August 17, 2017 - 11:02am | 390Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) peaked north of $250 per share in 2015, but by 2017 they dropped to a single digit. Needless to say, this represented a challenging time for the company. But since bottoming at $8.31 per share this year, the company has made "great...